Last updated on February 2019

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer

Brief description of study

The purpose of this study is to determine whether Nivolumab will improve overall survival, disease-free survival, or both compared with placebo.

Clinical Study Identifier: NCT02743494

Contact Investigators or Research Sites near you

Start Over

Site 0142

Local Institution
Tel Aviv, Israel
  Connect »

Site 0145

Local Institution
Ramat-gan, Israel
  Connect »

Site 0143

Local Institution
Petach Tikva, Israel
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.